|Bid||26.21 x 800|
|Ask||26.34 x 800|
|Day's Range||26.19 - 26.88|
|52 Week Range||6.83 - 54.84|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.33|
CAMBRIDGE, Mass., Jan. 02, 2019 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
On November 13, Solid Biosciences’ (SLDB) stock price closed at $31.94, which represents ~10.48% growth from the close of $28.91 on November 12. On November 13, Solid Biosciences’ stock price increased after it presented its third-quarter financial results.
Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE DMD Clinical Trial Company Plans to Report Preliminary Results from IGNITE DMD in the First Quarter of 2019.
CAMBRIDGE, Mass., Nov. 09, 2018 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on.
The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous year. The company just signed another high-profile Cell Therapy company, Iovance Biotherapeutics (IOVA), as a client, joining Crispr Therapeutics (CRSP) and Adaptimmune (ADAP) among others. As they continue to sign clients, grow revenue, and add global manufacturing capacity, valuation metrics suggest this NASDAQ listing could be substantially undervalued.
Solid Biosciences (SLDB) is focused on developing products that treat Duchenne muscular dystrophy (or DMD), a genetic muscle-wasting disease caused by mutations in the dystrophin gene. Solid Biosciences’ SGT-001 is being developed to restore functional dystrophin protein expression in patients’ muscles. The drug has received rare pediatric disease designation in the United States and orphan drug designation in the United States and the European Union.
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).
The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts ...
A manufacturing-related hold on Sarepta Therapeutics Inc (NASDAQ: SRPT )’s Duchenne muscular dystrophy candidate catalyzed a recent sell-off. Morgan Stanley sees a buying opportunity in the otherwise-lauded ...
Sarepta Therapeutics Inc (NASDAQ: SRPT ) announced a manufacturing-related hold Wednesday on its Phase 1/2 trial of microdystrophin gene therapy for Duchenne muscular dystrophy. Solid Biosciences Inc (NASDAQ: ...
Today, resTORbio (TORC) is trading at $13.36, which represents ~48.28% growth compared to yesterday. On July 24, resTORbio stock closed at $9.01, which represents ~19% growth from its 52-week low of $7.54 on April 10. TORC hit its 52-week high of $21.09 on February 26. Today, resTORbio announced positive results from its Phase 2b trial of RTB101 to evaluate the safety and efficacy of the drug in older individuals who are at high risk of morbidity and mortality due to respiratory tract infections.
The first half of 2018 brought Dropbox Inc (NASDAQ: DBX ), Spotify Technology SA (NYSE: SPOT ) and 118 other market newbies raising an aggregate $35.2 billion — the most since 2014. Bettors on the young ...
The Street grew more bullish on Solid Biosciences Inc (NASDAQ: SLDB ) last week following progress announcements on Solid and peer candidates. At least three analysts raised their valuation targets: The ...